Canaccord Genuity Upgrades Intercept Pharmaceuticals (ICPT) to Buy
Tweet
Share
E-mailGet Alerts ICPT Hot Sheet
Price: $19.00 --0%
Rating Summary:
13 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 2 | New: 1
Rating Summary:
13 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 2 | New: 1
Join SI Premium – FREE
Canaccord Genuity analyst Edward Nash upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Hold to Buy with a price target of $19.00 (from $12.00).
For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.
Shares of Intercept Pharmaceuticals closed at $10.90 yesterday.
You May Also Be Interested In
- Citi Upgrades Domino's Pizza Enterprises Ltd. (DMP:AU) (DPZUF) to Buy
- Mineral Resources Limited (MIN:AU) (MALRF) PT Lowered to AUD76 at UBS
- JCR Pharmaceuticals Co Ltd (4552:JP) PT Raised to JPY560 at Citi
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
